Recruiting PHASE1 INTERVENTIONAL 2-arm NCT05259709

A Study of ImmunoPet Imaging Using 89Zr-DFO-REGN5054 in Adult Participants With Solid Cancers Treated With Cemiplimab

A First-in-Human Study of 89Zr-DFO-REGN5054 (Anti-CD8) Positron Emission Tomography in Patients With Solid Malignancies Treated With Cemiplimab

Sponsor: Regeneron Pharmaceuticals

Conditions Advanced Solid Tumor Metastatic Solid Tumor

Interventions 89Zr˗DFO˗REGN5054 cemiplimab

Updated 10 times since 2022 Last updated: Sep 4, 2025 Started: Feb 7, 2023 Primary completion: Jan 6, 2027 Completion: Jan 6, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Advanced Solid Tumor and Metastatic Solid Tumor, this trial is actively recruiting participants. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 10 data snapshots since 2023. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

10 versions recorded

Oct 2025 — Present [monthly]

Recruiting PHASE1
Mar 2025 — Oct 2025 [monthly]

Recruiting PHASE1
Jan 2025 — Mar 2025 [monthly]

Recruiting PHASE1
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE1
Sep 2024 — Dec 2024 [monthly]

Recruiting PHASE1

▶ Show 5 earlier versions

Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Oct 2023 — Jul 2024 [monthly]

Recruiting PHASE1
Mar 2023 — Oct 2023 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Sep 2022 — Mar 2023 [monthly]

Not Yet Recruiting PHASE1
Mar 2022 — Sep 2022 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Regeneron Pharmaceuticals

Data source: Regeneron Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Groningen, Netherlands